Compound heterozygous CASQ2 mutations and long-term course of catecholaminergic polymorphic ventricular tachycardia

Katherine Josephs, Kunjan Patel, Christopher M. Janson, Cristina Montagna, Thomas V. McDonald

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a potentially lethal inherited cardiac disorder characterized by episodic ventricular tachycardia during adrenergic stimulation. It is associated with significant morbidity and mortality. Knowledge of the underlying genetic cause, pathogenesis, and the natural history of the disease remains incomplete. Approximately 50% of CPVT cases are caused by dominant mutations in the cardiac ryanodine receptor (RYR2) gene, <5% of cases are accounted for by recessive mutations in cardiac calsequestrin (CASQ2) or Triadin (TRDN). Methods: We report a family with two CASQ2 gene mutations. A research-based next-generation sequencing (NGS) initiative was used in a patient with a severe CPVT phenotype and her clinically unaffected son. Reverse transcription polymerase chain reaction (RT-PCR) from platelet RNA was used to assess the consequences of predicted splice variants. Results: NGS revealed that the proband carried a novel c.199C>T (p.Gln67*) mutation and a previously reported splice site mutation c.532+1G>A in CASQ2. Her son is a heterozygous carrier of the c.199C>T (p.Gln67*) mutation alone and the proband was compound heterozygous at CASQ2. RNA analysis demonstrated that the splice site mutation results in the retention of intron 3 with no full-length CASQ2 mRNA. Conclusion: This study describes a novel CPVT genotype and further characterizes the effect of a previously reported CASQ2 splice site mutation. The long-term follow-up of 23 years since first symptom provides additional insight into the natural history of CASQ2-associated CPVT.

Original languageEnglish (US)
Pages (from-to)788-794
Number of pages7
JournalMolecular Genetics and Genomic Medicine
Volume5
Issue number6
DOIs
StatePublished - Jan 1 2017

Fingerprint

Mutation
Ryanodine Receptor Calcium Release Channel
Ventricular Tachycardia
Natural History
Adrenergic Agents
Introns
Polymorphic catecholergic ventricular tachycardia
Genotype
RNA
Morbidity
Messenger RNA
Mortality
Genes

Keywords

  • alternative splicing
  • Atrial fibrillation
  • autosomal recessive
  • calsequestrin-2
  • catecholaminergic polymorphic ventricular tachycardia

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)
  • Molecular Biology
  • Medicine(all)

Cite this

Compound heterozygous CASQ2 mutations and long-term course of catecholaminergic polymorphic ventricular tachycardia. / Josephs, Katherine; Patel, Kunjan; Janson, Christopher M.; Montagna, Cristina; McDonald, Thomas V.

In: Molecular Genetics and Genomic Medicine, Vol. 5, No. 6, 01.01.2017, p. 788-794.

Research output: Contribution to journalArticle

Josephs, Katherine ; Patel, Kunjan ; Janson, Christopher M. ; Montagna, Cristina ; McDonald, Thomas V. / Compound heterozygous CASQ2 mutations and long-term course of catecholaminergic polymorphic ventricular tachycardia. In: Molecular Genetics and Genomic Medicine. 2017 ; Vol. 5, No. 6. pp. 788-794.
@article{91fcca1134754981a11558e5556cbd94,
title = "Compound heterozygous CASQ2 mutations and long-term course of catecholaminergic polymorphic ventricular tachycardia",
abstract = "Background: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a potentially lethal inherited cardiac disorder characterized by episodic ventricular tachycardia during adrenergic stimulation. It is associated with significant morbidity and mortality. Knowledge of the underlying genetic cause, pathogenesis, and the natural history of the disease remains incomplete. Approximately 50{\%} of CPVT cases are caused by dominant mutations in the cardiac ryanodine receptor (RYR2) gene, <5{\%} of cases are accounted for by recessive mutations in cardiac calsequestrin (CASQ2) or Triadin (TRDN). Methods: We report a family with two CASQ2 gene mutations. A research-based next-generation sequencing (NGS) initiative was used in a patient with a severe CPVT phenotype and her clinically unaffected son. Reverse transcription polymerase chain reaction (RT-PCR) from platelet RNA was used to assess the consequences of predicted splice variants. Results: NGS revealed that the proband carried a novel c.199C>T (p.Gln67*) mutation and a previously reported splice site mutation c.532+1G>A in CASQ2. Her son is a heterozygous carrier of the c.199C>T (p.Gln67*) mutation alone and the proband was compound heterozygous at CASQ2. RNA analysis demonstrated that the splice site mutation results in the retention of intron 3 with no full-length CASQ2 mRNA. Conclusion: This study describes a novel CPVT genotype and further characterizes the effect of a previously reported CASQ2 splice site mutation. The long-term follow-up of 23 years since first symptom provides additional insight into the natural history of CASQ2-associated CPVT.",
keywords = "alternative splicing, Atrial fibrillation, autosomal recessive, calsequestrin-2, catecholaminergic polymorphic ventricular tachycardia",
author = "Katherine Josephs and Kunjan Patel and Janson, {Christopher M.} and Cristina Montagna and McDonald, {Thomas V.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1002/mgg3.323",
language = "English (US)",
volume = "5",
pages = "788--794",
journal = "Molecular genetics & genomic medicine",
issn = "2324-9269",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Compound heterozygous CASQ2 mutations and long-term course of catecholaminergic polymorphic ventricular tachycardia

AU - Josephs, Katherine

AU - Patel, Kunjan

AU - Janson, Christopher M.

AU - Montagna, Cristina

AU - McDonald, Thomas V.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a potentially lethal inherited cardiac disorder characterized by episodic ventricular tachycardia during adrenergic stimulation. It is associated with significant morbidity and mortality. Knowledge of the underlying genetic cause, pathogenesis, and the natural history of the disease remains incomplete. Approximately 50% of CPVT cases are caused by dominant mutations in the cardiac ryanodine receptor (RYR2) gene, <5% of cases are accounted for by recessive mutations in cardiac calsequestrin (CASQ2) or Triadin (TRDN). Methods: We report a family with two CASQ2 gene mutations. A research-based next-generation sequencing (NGS) initiative was used in a patient with a severe CPVT phenotype and her clinically unaffected son. Reverse transcription polymerase chain reaction (RT-PCR) from platelet RNA was used to assess the consequences of predicted splice variants. Results: NGS revealed that the proband carried a novel c.199C>T (p.Gln67*) mutation and a previously reported splice site mutation c.532+1G>A in CASQ2. Her son is a heterozygous carrier of the c.199C>T (p.Gln67*) mutation alone and the proband was compound heterozygous at CASQ2. RNA analysis demonstrated that the splice site mutation results in the retention of intron 3 with no full-length CASQ2 mRNA. Conclusion: This study describes a novel CPVT genotype and further characterizes the effect of a previously reported CASQ2 splice site mutation. The long-term follow-up of 23 years since first symptom provides additional insight into the natural history of CASQ2-associated CPVT.

AB - Background: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a potentially lethal inherited cardiac disorder characterized by episodic ventricular tachycardia during adrenergic stimulation. It is associated with significant morbidity and mortality. Knowledge of the underlying genetic cause, pathogenesis, and the natural history of the disease remains incomplete. Approximately 50% of CPVT cases are caused by dominant mutations in the cardiac ryanodine receptor (RYR2) gene, <5% of cases are accounted for by recessive mutations in cardiac calsequestrin (CASQ2) or Triadin (TRDN). Methods: We report a family with two CASQ2 gene mutations. A research-based next-generation sequencing (NGS) initiative was used in a patient with a severe CPVT phenotype and her clinically unaffected son. Reverse transcription polymerase chain reaction (RT-PCR) from platelet RNA was used to assess the consequences of predicted splice variants. Results: NGS revealed that the proband carried a novel c.199C>T (p.Gln67*) mutation and a previously reported splice site mutation c.532+1G>A in CASQ2. Her son is a heterozygous carrier of the c.199C>T (p.Gln67*) mutation alone and the proband was compound heterozygous at CASQ2. RNA analysis demonstrated that the splice site mutation results in the retention of intron 3 with no full-length CASQ2 mRNA. Conclusion: This study describes a novel CPVT genotype and further characterizes the effect of a previously reported CASQ2 splice site mutation. The long-term follow-up of 23 years since first symptom provides additional insight into the natural history of CASQ2-associated CPVT.

KW - alternative splicing

KW - Atrial fibrillation

KW - autosomal recessive

KW - calsequestrin-2

KW - catecholaminergic polymorphic ventricular tachycardia

UR - http://www.scopus.com/inward/record.url?scp=85040695333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040695333&partnerID=8YFLogxK

U2 - 10.1002/mgg3.323

DO - 10.1002/mgg3.323

M3 - Article

VL - 5

SP - 788

EP - 794

JO - Molecular genetics & genomic medicine

JF - Molecular genetics & genomic medicine

SN - 2324-9269

IS - 6

ER -